Van Hemelrijck Mathias, Taramasso Maurizio, De Carlo Carlotta, Kuwata Shingo, Regar Evelyn, Nietlispach Fabian, Ferrero Adolfo, Weber Alberto, Maisano Francesco
Department of Cardiovascular Surgery, University Hospital Zürich, Rämistrasse 100, 8091 Zürich, Switzerland.
Department of Cardiology, University Hospital Zürich, Rämistrasse 100, 8091 Zürich, Switzerland.
F1000Res. 2018 Jan 16;7:58. doi: 10.12688/f1000research.11906.1. eCollection 2018.
Over the last few years, treatment of severe symptomatic aortic stenosis in high-risk patients has drastically changed to adopt a less-invasive approach. Transcatheter aortic valve implantation (TAVI) has been developed as a very reproducible and safe procedure, as shown in many trials. When compared to surgery, TAVI has produced superior, or at least comparable, results, and thus a trend to broaden treatment indications to lower-risk patients has erupted as a natural consequence, even though there is a lack of long-term evidence. In this review, we summarize and underline aspects that still remain unanswered that are compulsory if we want to enhance our understanding of this disease.
在过去几年中,高危患者严重症状性主动脉瓣狭窄的治疗已大幅转变为采用侵入性较小的方法。经导管主动脉瓣植入术(TAVI)已发展成为一种重复性高且安全的手术,许多试验都证明了这一点。与手术相比,TAVI产生了更优或至少相当的结果,因此,即使缺乏长期证据,将治疗适应症扩大到低风险患者的趋势也自然而然地出现了。在本综述中,我们总结并强调了一些仍未得到解答的方面,如果我们想加深对这种疾病的理解,这些方面是必须要考虑的。